A commentary notes that a 28-week extension phase of DEPICT-1 is now in progress and follow-up for longer than 1 year would be preferable because effects of adjunct therapies on glycaemic control in type 1 diabetes are not always sustained. It adds that regulators are likely to await at least the results of the 12-month follow-up, and data from other ongoing trials, before considering an indication for SGLT2 inhibitors in type 1 diabetes. Based on the findings from DEPICT-1, it suggests that adjunct therapy with SGLT2 inhibitors might be appropriate for individuals who have a good understanding of the early warning signs of ketoacidosis, undertake regular home monitoring (including of blood ketones), and have a high level of self-monitoring and communication with their diabetes team.